Systemic embolism in amyloid transthyretin cardiomyopathy

Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR‐CM), data about its incidence and prevalence are scarce. We studied the incidence, prevalence and factors associated with embolic events in ATTR‐CM. Additionally, we evaluated embolic events according to the type of oral anticoagulation (OAC) and the performance of the CHA2DS2‐VASc score in this setting.

[1]  P. Cintas,et al.  New Oral Anticoagulants vs. Vitamin K Antagonists Among Patients With Cardiac Amyloidosis: Prognostic Impact , 2021, Frontiers in Cardiovascular Medicine.

[2]  S. Solomon,et al.  Atrial Fibrillation and Ischemic Stroke with the Amyloidogenic V122I Transthyretin Variant among Black Americans. , 2021, Journal of the American College of Cardiology.

[3]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases , 2021, European journal of heart failure.

[4]  V. Nkomo,et al.  Persistence of Left Atrial Appendage Thrombus in Patients With Cardiac Amyloidosis. , 2021, Journal of the American College of Cardiology.

[5]  A. Petrie,et al.  Abstract 13148: Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis , 2020, Circulation.

[6]  C. Autore,et al.  Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation , 2020, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[7]  W. Saliba,et al.  Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. , 2020, JACC. Clinical electrophysiology.

[8]  Angelo B. Biviano,et al.  Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding , 2020, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  F. Domínguez,et al.  Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. , 2020, Revista espanola de cardiologia.

[10]  D. Darden,et al.  Management of Arrhythmias in Cardiac Amyloidosis. , 2020, JACC. Clinical electrophysiology.

[11]  S. Solomon,et al.  Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans , 2020, European journal of heart failure.

[12]  W. Saliba,et al.  No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis. , 2019, JACC. Clinical electrophysiology.

[13]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization , 2019, Journal of Nuclear Cardiology.

[14]  J. Moon,et al.  High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. , 2019, Journal of the American College of Cardiology.

[15]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[16]  S. Solomon,et al.  Left atrial structure and function in cardiac amyloidosis , 2017, European heart journal cardiovascular Imaging.

[17]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[18]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[19]  M. Skinner,et al.  Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study , 2016, Circulation.

[20]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[21]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[22]  Matthew W. Martinez,et al.  Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis , 2009, Circulation.

[23]  Krishnaswamy Chandrasekaran,et al.  Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis , 2007, Circulation.

[24]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[25]  R. Falk,et al.  Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. , 1995, British heart journal.